Repligen (RGEN) Director Martin D. Madaus Receives Restricted Stock Award

What Happened

• Martin D. Madaus, a member of Repligen Corporation's board of directors, received equity awards on May 14, 2026: 995 restricted stock units (RSUs) and 2,239 units reported as derivative awards, for a total of 3,234 units. The reported acquisition price for both items is $0.00 (no cash paid); the filing does not list a dollar value for the grant.

Key Details

• Transaction date: 2026-05-14 (Form 4 filed 2026-05-18).
• Award amounts: 995 RSUs (reported as shares acquired) and 2,239 RSU-style derivative units (reported as a derivative acquisition); combined total = 3,234 units.
• Price: $0.00 reported for both items (no cash paid).
• Vesting: Awards vest in full on the earlier of May 14, 2027, one year from grant, or the date of the next annual shareholders’ meeting (per footnotes).
• Settlement/deferral: The 995 RSUs may be deferred under Repligen’s Deferred Compensation Plan for Non‑Employee Directors; settlement will be in shares upon vesting and following the director’s separation of service (per footnote).
• Shares owned after transaction: Not specified in the filing.
• Filing timing: Form 4 was filed May 18 for the May 14 grant (filed four days after the transaction); investors may note whether this meets the SEC’s 2-business-day reporting expectation.

Context

• These awards are compensation grants (not market purchases or sales). RSUs are a contingent right to receive shares upon vesting; they do not represent immediately tradable stock until settled. Such director awards are commonly used for non-employee director compensation and do not by themselves indicate a buy or sell decision in the open market.